Sam Brusco, Associate Editor03.13.23
Stacey Stevens, president of cancer detection and therapy solutions company iCAD, has resigned for personal reasons. Stevens will remain with the company until April 30 to create a smooth transition to new leadership. The board named Dana Brown as the new president and CEO, and Brown will remain as chairman of the board.
Steven spent over 16 years with iCAD, joining as VP of marketing and strategy in 2006. Her marketing and strategy, sales, and partnership building skills helped create a foundational structure that will serve iCAD for years to come.
“We cannot thank Ms. Stevens enough for the commitment, passion, creativity, and enthusiasm she has given iCAD during her tenure,” Dr. Susan Wood, member of iCAD’s Board of Directors and Chairman of the Compensation Committee, told the press.
“Dana takes the reins of this great company at a time of transformation, and the Board has every confidence that she is the best leader to set the vision and drive the plans for the Company’s continued success and growth. She has the right mix of skills and experience to lead us forward having run large, complex technology organizations, delivered strong financial and operational results in the face of turnarounds, and overseen strategy and innovation for the world’s leading breast cancer organization,” said Dr. Rakesh Patel, member of iCAD’s Board of Directors and Chairman of the Nominating and Corporate Governance committee.
Brown said, “I'm thrilled to be leading this incredible company. Working alongside our talented team, our Board, our clients and partners, I am committed to upholding our vision to be the world’s most pervasive and personalized suite of AI cancer detection solutions for our shareholders and stakeholders. Breast cancer is the most common cancer in women worldwide and the second leading cause of cancer death among women in the U.S. With iCAD’s early detection technology, we have the ability to detect cancers early thereby giving individuals the opportunity for more positive outcomes and more lives saved. I am energized by this challenge and look forward to guiding iCAD’s continued success.”
Steven spent over 16 years with iCAD, joining as VP of marketing and strategy in 2006. Her marketing and strategy, sales, and partnership building skills helped create a foundational structure that will serve iCAD for years to come.
“We cannot thank Ms. Stevens enough for the commitment, passion, creativity, and enthusiasm she has given iCAD during her tenure,” Dr. Susan Wood, member of iCAD’s Board of Directors and Chairman of the Compensation Committee, told the press.
“Dana takes the reins of this great company at a time of transformation, and the Board has every confidence that she is the best leader to set the vision and drive the plans for the Company’s continued success and growth. She has the right mix of skills and experience to lead us forward having run large, complex technology organizations, delivered strong financial and operational results in the face of turnarounds, and overseen strategy and innovation for the world’s leading breast cancer organization,” said Dr. Rakesh Patel, member of iCAD’s Board of Directors and Chairman of the Nominating and Corporate Governance committee.
Brown said, “I'm thrilled to be leading this incredible company. Working alongside our talented team, our Board, our clients and partners, I am committed to upholding our vision to be the world’s most pervasive and personalized suite of AI cancer detection solutions for our shareholders and stakeholders. Breast cancer is the most common cancer in women worldwide and the second leading cause of cancer death among women in the U.S. With iCAD’s early detection technology, we have the ability to detect cancers early thereby giving individuals the opportunity for more positive outcomes and more lives saved. I am energized by this challenge and look forward to guiding iCAD’s continued success.”